Since it has been previously established that TβRIII can modulate TGF-β signaling[6,43-46], it is not surprising that TβRIII has been shown to have both pro- and anti-tumorigenic effects in breast cancer. This evidence concerns the gene TGFB1 and breast carcinoma.